CH
CHGCY.US Chugai Pharmaceutical Co Ltd ADR
- Market cap
- USD 74.1B
- P/E
- 23.2x
- P/B
- 5.55x
- ROE
- 24.2%
- Dividend yield
- 2.96%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CHGCY.US undervalued?
Graham numberCHGCY.US trades 139.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chugai Pharmaceutical Co Ltd ADR fundamental analysis
No fundamental analysis for Chugai Pharmaceutical Co Ltd ADR yet.
Chugai Pharmaceutical Co Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chugai Pharmaceutical Co Ltd ADR
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding human…
Full company profileChugai Pharmaceutical Co Ltd ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chugai Pharmaceutical Co Ltd ADR annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 492B | 534B | 580B | 686B | 787B | 1,000B | 1.26T | 1.11T | 1.17T | 1.32T | 1.44T |
| Gross Profit | 244B | 280B | 317B | 420B | 513B | 662B | 784B | 698B | 831B | 938B | 1.01T |
| Operating Income | 76.9B | 98.9B | 124B | 211B | 301B | 422B | 533B | 439B | 542B | 619B | 708B |
| EBITDA | 93.3B | 115B | 122B | 234B | 329B | 450B | 565B | 476B | 576B | 662B | 708B |
| Net Income | 53.6B | 72.7B | 92.5B | 158B | 215B | 303B | 374B | 325B | 387B | 455B | 505B |
| EPS | 16 | 22 | 28 | 48 | 65 | 92 | 114 | 99 | 118 | 138 | 154 |
| Balance Sheet | |||||||||||
| Total Assets | 806B | 852B | 920B | 1.06T | 1.24T | 1.54T | 1.87T | 1.93T | 2.21T | 2.47T | 2.37T |
| Total Liabilities | 160B | 160B | 163B | 205B | 255B | 351B | 445B | 307B | 307B | 443B | 286B |
| Shareholders' Equity | 646B | 692B | 756B | 854B | 980B | 1.19T | 1.42T | 1.63T | 1.90T | 2.03T | 2.09T |
| Cash & Short-term Investments | 206B | 243B | 249B | 333B | 379B | 472B | 503B | 739B | 996B | 980B | 869B |
| Total Debt | 645M | 336M | 215M | 12.8B | 4.64B | 16.0B | 14.1B | 13.5B | 10.9B | 25.7B | 16.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 38.8B | 108B | 119B | 207B | 205B | 280B | 244B | 410B | 448B | 408B | 417B |
| Capital Expenditure | 36.4B | 44.5B | 77.7B | 61.2B | 61.4B | 72.9B | 71.2B | 74.3B | 54.9B | 80.0B | 77.9B |
| Free Cash Flow | 2.37B | 63.1B | 41.4B | 145B | 144B | 207B | 173B | 336B | 393B | 328B | 340B |
| Ratios | |||||||||||
| ROE | 8.3% | 10.5% | 12.2% | 18.4% | 21.9% | 25.5% | 26.3% | 20.0% | 20.4% | 22.4% | 24.2% |
| ROA | 6.6% | 8.5% | 10.1% | 14.9% | 17.4% | 19.7% | 20.0% | 16.8% | 17.5% | 18.4% | 21.3% |
| Net Profit Margin | 10.9% | 13.6% | 16.0% | 23.0% | 27.3% | 30.3% | 29.7% | 29.3% | 33.1% | 34.5% | 35.1% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chugai Pharmaceutical Co Ltd ADR dividends
- Dividend yield
- 2.96%
- Forward dividend
- 0.67 USD
- Payout ratio
- 69.0%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | JPY 314B | 95 | 69.0% |
| 2024 | JPY 133B | 40 | 34.4% |
| 2023 | JPY 132B | 40 | 40.4% |
| 2022 | JPY 138B | 42 | 36.9% |
| 2021 | JPY 98.6B | 30 | 32.6% |
| 2020 | JPY 91.4B | 28 | 42.6% |
| 2019 | JPY 56.4B | 17 | 35.8% |
| 2018 | JPY 35.0B | 11 | 37.9% |
| 2017 | JPY 30.1B | 9.15 | 41.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12:1 on Jul 6, 2020.
Who owns Chugai Pharmaceutical Co Ltd ADR
- Insiders 0.00%
- Institutions 0.05%
- Public & others 99.95%
- Shares outstanding 3.29B
- Free float 1.28B
Chugai Pharmaceutical Co Ltd ADR company profile
- Company name
- Chugai Pharmaceutical Co Ltd ADR
- Ticker
- CHGCY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,104
- Fiscal year end
- December
- Address
- Nihonbashi Mitsui Tower, Chuo, Japan, 103-8324
- Phone
- 81 3 3281 6611
- Website
- chugai-pharm.co.jp
About Chugai Pharmaceutical Co Ltd ADR
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Chugai Pharmaceutical Co Ltd ADR management
10- Dr. Osamu OkudaPresident, CEO & Chairman · born 1963
- Mr. Iwaaki TaniguchiSenior Executive Officer, CFO, Head of Finance & Director · born 1966
- Toshiya SasaiExecutive of Investor Relations Group & Corporate Communications Department
- Junichi TakanoHead of Marketing & Sales Division
- Mr. Shinji HidakaExecutive Vice President
- Mr. Tetsuya YamaguchiExecutive Vice President
- Mr. Yoshiyuki YanoExecutive Vice President
- Mr. Kosuke IijimaHead of PHC Solution Department
- Dr. Tomoyuki Igawa Ph.D.VP & Head of Research Division
- Dr. Kaori OuchiExecutive Vice President